ABUS
Price
$1.90
Change
-$0.03 (-1.55%)
Updated
Sep 25, 6:59 PM EST
43 days until earnings call
AGEN
Price
$1.14
Change
-$0.04 (-3.39%)
Updated
Sep 25, 6:59 PM EST
42 days until earnings call

Compare trend and price ABUS vs AGEN

Header iconABUS vs AGEN Comparison
Open Charts ABUS vs AGENBanner chart's image
Arbutus Biopharma
Price$1.90
Change-$0.03 (-1.55%)
Volume$517.41K
CapitalizationN/A
Agenus
Price$1.14
Change-$0.04 (-3.39%)
Volume$2.06M
CapitalizationN/A
View a ticker or compare two or three
ABUS vs AGEN Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ABUS vs. AGEN commentary
Sep 26, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and AGEN is a Hold.

COMPARISON
Comparison
Sep 26, 2023
Stock price -- (ABUS: $1.90 vs. AGEN: $1.14)
Brand notoriety: ABUS and AGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 120% vs. AGEN: 76%
Market capitalization -- ABUS: $323.38M vs. AGEN: $447.9M
ABUS [@Biotechnology] is valued at $323.38M. AGEN’s [@Biotechnology] market capitalization is $447.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $410.21B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileAGEN’s FA Score has 0 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • AGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, ABUS is a better buy in the long-term than AGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 4 TA indicator(s) are bullish while AGEN’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 4 bullish, 5 bearish.
  • AGEN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AGEN is a better buy in the short-term than ABUS.

Price Growth

ABUS (@Biotechnology) experienced а -4.52% price change this week, while AGEN (@Biotechnology) price change was -8.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.83%. For the same industry, the average monthly price growth was +22.16%, and the average quarterly price growth was +34.16%.

Reported Earning Dates

ABUS is expected to report earnings on Nov 08, 2023.

AGEN is expected to report earnings on Nov 07, 2023.

Industries' Descriptions

@Biotechnology (-3.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ABUS with price predictions.
OPEN
A.I.dvisor published
a Summary for AGEN with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
AGEN($448M) has a higher market cap than ABUS($323M). ABUS YTD gains are higher at: -18.455 vs. AGEN (-51.595). ABUS has higher annual earnings (EBITDA): -70.5M vs. AGEN (-197.96M). AGEN (158M) and ABUS (152M) have equal amount of cash in the bank . ABUS has less debt than AGEN: ABUS (2.04M) vs AGEN (87.3M). AGEN has higher revenues than ABUS: AGEN (99.4M) vs ABUS (23.5M).
ABUSAGENABUS / AGEN
Capitalization323M448M72%
EBITDA-70.5M-197.96M36%
Gain YTD-18.455-51.59536%
P/E RatioN/A12.89-
Revenue23.5M99.4M24%
Total Cash152M158M96%
Total Debt2.04M87.3M2%
FUNDAMENTALS RATINGS
ABUS vs AGEN: Fundamental Ratings
ABUS
AGEN
OUTLOOK RATING
1..100
6966
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
97
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
8288
P/E GROWTH RATING
1..100
10066
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABUS's Valuation (45) in the Biotechnology industry is somewhat better than the same rating for AGEN (97). This means that ABUS’s stock grew somewhat faster than AGEN’s over the last 12 months.

ABUS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AGEN (100). This means that ABUS’s stock grew similarly to AGEN’s over the last 12 months.

ABUS's SMR Rating (96) in the Biotechnology industry is in the same range as AGEN (100). This means that ABUS’s stock grew similarly to AGEN’s over the last 12 months.

ABUS's Price Growth Rating (82) in the Biotechnology industry is in the same range as AGEN (88). This means that ABUS’s stock grew similarly to AGEN’s over the last 12 months.

AGEN's P/E Growth Rating (66) in the Biotechnology industry is somewhat better than the same rating for ABUS (100). This means that AGEN’s stock grew somewhat faster than ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSAGEN
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 16 days ago
80%
Bullish Trend 14 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
80%
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYVAX244.033.58
+1.49%
Rydex Energy Services H
FDGFX30.450.11
+0.36%
Fidelity® Dividend Growth
LDIGX13.45N/A
N/A
Franklin Global Dividend FI
MCSDX31.37N/A
N/A
MainStay WMC Enduring Capital R6
FGDAX20.41-0.24
-1.16%
Fidelity Advisor® Gold A

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with MDGL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
-1.55%
MDGL - ABUS
48%
Loosely correlated
-1.57%
ICPT - ABUS
45%
Loosely correlated
-0.38%
ARRY - ABUS
43%
Loosely correlated
-1.99%
AXON - ABUS
42%
Loosely correlated
-1.12%
ORMP - ABUS
42%
Loosely correlated
-0.38%
More

AGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGEN has been loosely correlated with INO. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if AGEN jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGEN
1D Price
Change %
AGEN100%
-3.39%
INO - AGEN
52%
Loosely correlated
-4.77%
BEAM - AGEN
52%
Loosely correlated
-3.16%
NTLA - AGEN
51%
Loosely correlated
-0.56%
CRSP - AGEN
51%
Loosely correlated
+0.81%
ATRA - AGEN
49%
Loosely correlated
-8.94%
More